Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.

Markwalder JA, Arnone MR, Benfield PA, Boisclair M, Burton CR, Chang CH, Cox SS, Czerniak PM, Dean CL, Doleniak D, Grafstrom R, Harrison BA, Kaltenbach RF 3rd, Nugiel DA, Rossi KA, Sherk SR, Sisk LM, Stouten P, Trainor GL, Worland P, Seitz SP.

J Med Chem. 2004 Nov 18;47(24):5894-911.

PMID:
15537345
2.

Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.

Nugiel DA, Etzkorn AM, Vidwans A, Benfield PA, Boisclair M, Burton CR, Cox S, Czerniak PM, Doleniak D, Seitz SP.

J Med Chem. 2001 Apr 26;44(9):1334-6. No abstract available.

PMID:
11311054
3.

Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments.

Wexler EJ, Gravallese EM, Czerniak PM, Devenny JJ, Longtine J, Wong MK, Slee AM, Kerr JS.

Clin Cancer Res. 2000 Aug;6(8):3361-70.

4.

Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo.

Jaffee BD, Manos EJ, Collins RJ, Czerniak PM, Favata MF, Magolda RL, Scherle PA, Trzaskos JM.

Biochem Biophys Res Commun. 2000 Feb 16;268(2):647-51.

PMID:
10679258
5.

Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.

Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A Jr, Slee AM.

Anticancer Res. 1999 Mar-Apr;19(2A):959-68.

PMID:
10368639
6.

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, et al.

Nature. 1995 Nov 23;378(6555):406-9.

PMID:
7477380
7.

Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.

McRipley RJ, Burns-Horwitz PE, Czerniak PM, Diamond RJ, Diamond MA, Miller JL, Page RJ, Dexter DL, Chen SF, Sun JH, et al.

Cancer Res. 1994 Jan 1;54(1):159-64.

8.

XB596, a promising bis-naphthalimide anti-cancer agent.

Chen SF, Behrens DL, Behrens CH, Czerniak PM, Dexter DL, Dusak BL, Fredericks JR, Gale KC, Gross JL, Jiang JB, et al.

Anticancer Drugs. 1993 Aug;4(4):447-57.

PMID:
8400347

Supplemental Content

Loading ...
Support Center